The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Principles of antibacterial dosing in continuous renal replacement therapy
Abstract
OBJECTIVES: To outline the concepts involved in optimizing antibacterial dosing in critically ill patients with acute renal failure undergoing continuous renal replacement therapy (CRRT), provide a strategy for optimizing dosing, and summarize the data required to implement the strategy. DATA SOURCES: MEDLINE search from February 1986 to 2008. DATA EXTRACTION AND SYNTHESIS: Optimal dosing of antibacterials is dependent on achieving pharmacokinetic targets associated with maximal killing of bacteria and improved outcomes. The initial dose is dependent on the volume of distribution. Maintenance doses are dependent on clearance. Both should be adjusted according to the pharmacokinetic target associated with optimal bacterial killing, when known. The volume of distribution of some antibacterials is altered by critical illness or acute renal failure or both. Clearance by CRRT is dependent on the dose and mode of CRRT and the sieving or saturation coefficient of the drug. Both sieving and saturation coefficient are related to the plasma protein binding and thus may be altered in renal failure. CONCLUSIONS: Appropriate dose calculation requires knowledge of the pharmacokinetic target and the usual minimum inhibitory concentration of the suspected organism in the patient's locality (or if unavailable, the break point for the organism), published pharmacokinetic data (volume of distribution, non-CRRT clearance) on critically ill patients receiving CRRT (which may differ substantially from noncritically ill patients or those without renal failure), the sieving or saturation coefficient of the relevant drug in critically ill patients, the dose and mode of CRRT being used, and the actual dose of CRRT that is delivered. This large number of variables results in considerable inter- and intrapatient heterogeneity in dose requirements. This article provides basic principles and relevant data to guide the clinician in prescribing individualized dosing regimes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 17×
“Route of dilution NS NA NS Mean SD 23 7 ml/kg/hr NA 0.21 0.09 NA 4 g 8 hourly Mean SD 3.42 0.54 L/hr NA NA 0.90 0.33 500–750 mg 12 hourly 1–2 L/hr NA NA NA Initial 1.5 g, then 750 mg 20–24 hourly Mean SD 0.85 0.11 L/hr Not critically ill NA NA 0.86 0.08 500 mg 12 hourly 1–2 L/hr NA 0.69 0.18 NA 2 g 8 hourly (MIC 4 mg/…”
BackgroundInfluentialThe natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
Rangel-Frausto, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.117 · Cited by 2,104
Pathogenetic Mechanisms of Septic Shock
Epstein, F. H., & Parrillo, J. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282008 · Cited by 1,548
Acute Renal Failure and Sepsis
Schrier, R. W., & Wang, W. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032401 · Cited by 1,260
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Septic Acute Kidney Injury in Critically Ill Patients: Clinical Characteristics and Outcomes
Bagshaw, S. M., Uchino, S., Bellomo, R., Morimatsu, H., Morgera, S., Schetz, M., Tan, I., Bouman, C., Macedo, E., Gibney, N., et al. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03681106 · Cited by 888
Calandra, T., & Cohen, J. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000168253.91200.83 · Cited by 839
Rybak, M. J., Lomaestro, B. M., Rotscahfer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · Clinical Infectious Diseases · doi:10.1086/600877 · Cited by 815
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Research works printed but not linked: 57
- Rahman, 2002, Clin Med, 2, 108, 10.7861/clinmedicine.2-2-108 · doi:10.7861/clinmedicine.2-2-108
- Rangel-Frausto, 1995, JAMA, 273, 117, 10.1001/jama.1995.03520260039030 · DOI · Paper page
- Kubin, 2005, J Pharm Pract, 18, 109, 10.1177/0897190004273596 · doi:10.1177/0897190004273596
- Burgess, 1999, Chest, 115, 19S, 10.1378/chest.115.suppl_1.19S · DOI
- Tessier, 1999, Chemotherapy, 45, 284, 10.1159/000007198 · doi:10.1159/000007198
- Ronco, 2001, Nephrol Dial Transplant, 16, 67, 10.1093/ndt/16.suppl_5.67 · doi:10.1093/ndt/16.suppl_5.67
- Oda, 2002, Ther Apher, 6, 193, 10.1046/j.1526-0968.2002.00431.x · doi:10.1046/j.1526-0968.2002.00431.x
- Golper, 1998, Kidney Int Suppl, 66, S165
- Golper, 2001, Contrib Nephrol, &NA;, 349, 10.1159/000060103 · doi:10.1159/000060103
- Guenter, 2002, Pharmacotherapy, 22, 175, 10.1592/phco.22.3.175.33546 · doi:10.1592/phco.22.3.175.33546
- Malone, 2001, Antimicrob Agents Chemother, 45, 2949, 10.1128/AAC.45.10.2949-2954.2001 · doi:10.1128/aac.45.10.2949-2954.2001
- Hansen, 2001, Intensive Care Med, 27, 371, 10.1007/s001340000836 · doi:10.1007/s001340000836
- Traunmüller, 2001, J Antimicrob Chemother, 47, 229, 10.1093/jac/47.2.229 · doi:10.1093/jac/47.2.229
- Choi, 2004, Int J Antimicrob Agents, 24, 468
- Troyanov, 2003, Nephrol Dial Transplant, 18, 961, 10.1093/ndt/gfg055 · doi:10.1093/ndt/gfg055
- Lipman, 1998, Antimicrob Agents Chemother, 42, 2235, 10.1128/AAC.42.9.2235 · doi:10.1128/aac.42.9.2235
- Wallis, 2001, Intensive Care Med, 27, 665, 10.1007/s001340100857 · doi:10.1007/s001340100857
- Giles, 2000, Crit Care Med, 28, 632, 10.1097/00003246-200003000-00005 · doi:10.1097/00003246-200003000-00005
- Ververs, 2000, Crit Care Med, 28, 3412, 10.1097/00003246-200010000-00006 · doi:10.1097/00003246-200010000-00006
- Isla, 2007, Chemotherapy, 53, 194, 10.1159/000100864 · DOI
- Hassan, 1987, Antimicrob Agents Chemother, 31, 1855, 10.1128/AAC.31.11.1855 · doi:10.1128/aac.31.11.1855
- Jones, 1997, J Antimicrob Chemother, 40, 121, 10.1093/jac/40.1.121 · doi:10.1093/jac/40.1.121
- Tian, 2008, Antimicrob Agents Chemother, 52, 1009, 10.1128/AAC.00858-07 · doi:10.1128/aac.00858-07
- Meyers, 1983, Antimicrob Agents Chemother, 24, 812, 10.1128/AAC.24.5.812 · doi:10.1128/aac.24.5.812
- Gonzalez, 1985, Clin Pharmacol Ther, 37, 633, 10.1038/clpt.1985.102 · doi:10.1038/clpt.1985.102
- de Pont, 2007, Curr Opin Crit Care, 13, 668, 10.1097/MCC.0b013e3282f0febd · doi:10.1097/mcc.0b013e3282f0febd
- Tian, 2008, Artif Organs, 32, 81, 10.1111/j.1525-1594.2007.00460.x · doi:10.1111/j.1525-1594.2007.00460.x
- Leone, 2004, Antimicrob Agents Chemother, 48, 638, 10.1128/AAC.48.2.638-640.2004 · doi:10.1128/aac.48.2.638-640.2004
- Rubinstein, 2002, J Antimicrob Chemother, 49, 593, 10.1093/jac/49.4.593 · doi:10.1093/jac/49.4.593
- Capellier, 1998, Crit Care Med, 26, 88, 10.1097/00003246-199801000-00021 · doi:10.1097/00003246-199801000-00021
- Keller, 1995, Clin Nephrol, 43, S20
- Meyer, 2003, Kidney Blood Press Res, 26, 135, 10.1159/000070997 · doi:10.1159/000070997
- Davies, 1991, Nephrol Dial Transplant, 6, 971, 10.1093/ndt/6.12.971 · doi:10.1093/ndt/6.12.971
- Weiss, 1988, Clin Nephrol, 30, 282
- Traunmuller, 2002, J Antimicrob Chemother, 49, 129, 10.1093/jac/49.1.129 · doi:10.1093/jac/49.1.129
- Matzke, 2000, Antimicrob Agents Chemother, 44, 1639, 10.1128/AAC.44.6.1639-1644.2000 · DOI
- Kroh, 1996, J Clin Pharmacol, 36, 1114, 10.1002/j.1552-4604.1996.tb04164.x · doi:10.1002/j.1552-4604.1996.tb04164.x
- Isla, 2005, Clin Ther, 27, 599, 10.1016/j.clinthera.2005.05.004 · DOI
- Keller, 1989, Nephrol Dial Transplant, 4, 640
- Tegeder, 1997, Antimicrob Agents Chemother, 41, 2640, 10.1128/AAC.41.12.2640 · doi:10.1128/aac.41.12.2640
- Hashimoto, 1997, ASAIO J, 43, 84
- Tegeder, 1999, Clin Pharmacol Ther, 65, 50, 10.1016/S0009-9236(99)70121-9 · doi:10.1016/s0009-9236(99)70121-9
- Fuhrmann, 2004, J Antimicrob Chemother, 54, 780, 10.1093/jac/dkh421 · doi:10.1093/jac/dkh421
- Barrie, 1992, Intensive Care Med, 18, 437, 10.1007/BF01694350 · doi:10.1007/bf01694350
- DelDot, 2004, Br J Clin Pharmacol, 58, 259, 10.1111/j.1365-2125.2004.02143.x · doi:10.1111/j.1365-2125.2004.02143.x
- Boereboom, 1999, Intensive Care Med, 25, 1100, 10.1007/s001340051018 · doi:10.1007/s001340051018
- Yagasaki, 2003, Intensive Care Med, 29, 2094, 10.1007/s00134-003-1914-9 · doi:10.1007/s00134-003-1914-9
- Pea, 2001, Drug Monit, 23, 587, 10.1097/00007691-200110000-00013 · doi:10.1097/00007691-200110000-00013
- Wolter, 1994, Eur J Clin Pharmacol, 46, 179, 10.1007/BF00199886 · doi:10.1007/bf00199886
- Zarowitz, 1986, J Clin Pharmacol, 26, 686, 10.1002/j.1552-4604.1986.tb02973.x · doi:10.1002/j.1552-4604.1986.tb02973.x
- Ernest, 1992, Crit Care Med, 20, 586, 10.1097/00003246-199205000-00007 · doi:10.1097/00003246-199205000-00007
- Syka, 2005, J Clin Pharmacol, 45, 477, 10.1177/0091270004273949 · doi:10.1177/0091270004273949
- Robert, 1991, Crit Care Med, 19, 588, 10.1097/00003246-199104000-00029 · doi:10.1097/00003246-199104000-00029
- Moon, 2006, Korean J Nephrol, 25, 595
- Pea, 2004, Am J Kidney Dis, 44, 1097, 10.1053/j.ajkd.2004.08.032 · doi:10.1053/j.ajkd.2004.08.032
- Meyer, 2005, J Antimicrob Chemother, 56, 172, 10.1093/jac/dki133 · doi:10.1093/jac/dki133
- Churchwell, 2006, Blood Purif, 24, 548, 10.1159/000097078 · doi:10.1159/000097078
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationAntimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Self-citationThe Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Blot, S. I., Pea, F., & Lipman, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.006 · Cited by 444
Self-citationVeiga, R. P., & Paiva, J.-A. (2018) · Critical Care · doi:10.1186/s13054-018-2155-1 · Cited by 203
Wong, G., Briscoe, S., McWhinney, B., Ally, M., Ungerer, J., Lipman, J., & Roberts, J. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky314 · Cited by 169
Self-citationSurviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Zander, J., Maier, B., Suhr, A., Zoller, M., Frey, L., Teupser, D., & Vogeser, M. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0746 · Cited by 85
Barco, S., Bandettini, R., Maffia, A., Tripodi, G., Castagnola, E., & Cangemi, G. (2015) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000209 · Cited by 46
Metadata
- Authors
- Choi, G., Gomersall, C. D., Tian, Q., Joynt, G. M., Freebairn, R., & Lipman, J.
- Venue
- Critical Care Medicine
- Published
- 2009-07
- Volume
- 37
- Issue
- 7
- Pages
- 2268-2282
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2017487363
- Cited by
- 334
- References
- 95
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.